Videos
What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head…
Read MoreFrancesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, discusses a promising new technology that could enable much earlier detection…
Read MoreVicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, reports on Phase II data of lead candidate Luminate as sequential and combination therapy…
Read MoreOpthea CEO & Managing Director Megan Baldwin, PhD, updates the status of Phase I and II dose-escalation studies of the company’s lead agent OPT-302 in…
Read MoreCEO Jeff Cleland, PhD, reports the company is moving ahead with trial design for a single ascending-dose study of its candidate GB-102 for intravitreal injection…
Read MoreCharles Semba, MD, played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer…
Read MoreStephen Yoo, MD, chief medical officer of REGENXBIO, which utilizes adeno-associated virus to target disease, laid out the company’s plans to run its RGX-314 gene…
Read MoreOscar Cuzzani, MD, PhD, VP of clinical development, detailed the company’s two ophthalmology programs including cell replacement that could be used to treat dry AMD.…
Read MoreMohamed Genead, MD, chief medical officer of GenSight Biologics, updated OIS on the early-stage clinical progress of the company’s lead gene therapy product to treat…
Read MoreAndre Witkin, MD, assistant professor, Tufts University School of Medicine, explains how OCT angiography could allow researchers to better visualize neovascular membranes. The images could…
Read MoreAmir H. Kashani, MD, PhD, assistant professor of clinical ophthalmology, USC Roski Eye Institute, Keck Medicine of USC, demonstrates how a layered construction of OCT…
Read MoreM. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, introduces a promising new technology that could enable much earlier…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.